UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
Authors
Keywords
Advanced colorectal cancer, Irinotecan-based chemotherapy, <em class=EmphasisTypeItalic >UGT1A1</em>, Polymorphism, Uygur nationality, Han nationality, Toxicity, Clinical efficacy
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 1, Pages 119-130
Publisher
Springer Nature
Online
2016-05-25
DOI
10.1007/s00280-016-3057-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of UGT1A1 * 28 and * 6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients
- (2016) Chalirmporn Atasilp et al. Drug Metabolism and Pharmacokinetics
- Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
- (2016) Christophe Bounaix Morand du Puch et al. Journal of Translational Medicine
- Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
- (2016) Mi-Jung Kim et al. Cancer Research and Treatment
- PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
- (2016) Benoist Chibaudel et al. Cancer Medicine
- A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
- (2015) Bengt Gustavsson et al. Clinical Colorectal Cancer
- Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
- (2015) Ken-ichi Fujita WORLD JOURNAL OF GASTROENTEROLOGY
- The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
- (2015) Xiaoguang Xiao et al. OncoTargets and Therapy
- UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
- (2014) Lei Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- UGT1A1*28 and Other UGT1A Polymorphisms as Determinants of Irinotecan Toxicity
- (2014) P. Biason et al. JOURNAL OF CHEMOTHERAPY
- Development of Pyrosequencing Method for Detection ofUGT1A1Polymorphisms in Thai Colorectal Cancers
- (2014) Chonlaphat Sukasem et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)
- (2014) Hiroshi Soeda et al. ONCOLOGY
- UGT1A1 Gene Polymorphisms and the Toxicities of FOLFIRI in Chinese Han Patients with Gastrointestinal Cancer
- (2013) Chen-fei Zhou et al. Anti-Cancer Agents in Medicinal Chemistry
- The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
- (2013) Yi-Jing Chen et al. BIOMARKERS
- Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
- (2013) Lucía Cortejoso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- UGT1A1*6,1A7*3, and1A9*22genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
- (2013) Shoichi Hazama et al. CANCER SCIENCE
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians
- (2013) Xiang Liu et al. PLoS One
- Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy
- (2013) Kazuyuki Inoue et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
- (2012) Yan Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
- (2009) Glenn E Palomaki et al. GENETICS IN MEDICINE
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
- (2009) Christoph Schulz et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started